Share French medication intelligence company Synapse Medicine has rolled-out its Medication Shield technology in collaboration with the regional pharmacovigilance centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM). The technology claims to increase the safety of the COVID-19 vaccination campaign in France by managing the adverse drug reactions (ADRs) signals on a reporting portal, which is implemented by the French Ministry of Health. The reactions are encoded automatically into a standardised international terminology (MedDRA) which ranks them by severity. Synapse Medicine has been working in collaboration with the health institutions for the last 18 months on the management of pharmacovigilance cases. They have since published an infographic explaining how the Medication Shield technology is integrated into the French pharmacovigilance system.